tesaro releas result today zejula sale million
exceed estim million consensu million
better estim sale result unit demand increas strong growth
outsid us total revenu million lower estim
million due varubi collabor revenu million lower
estim million consensu million total oper expens
million higher estim million due lower
estim expens tesaro lost per share compar estim loss
per share consensu loss per share
zejula outlook basic unchang adjust revenu
outlook account lower varubi sale increas estim
 account current level pipelin invest along
adjust net interest expens result loss per share
slightli increas ep reduc
tesaro announc initi phase first trial zejula
/- bevacizumab first-lin ovarian cancer
tesaro announc enrol phase prima trial zejula
monotherapi patient first-lin ovarian cancer regardless biomark
statu complet
tesaro announc expect submit snda quadra studi
tesaro announc target submiss supplement new drug
applic snda zejula late-lin treatment ovarian patient beyond
brca mutat base quadra ye
focus
develop therapi cancer
found two market
product varubi rolapit zejula
analyst certif import disclosur see disclosur
anticip tesaro continu develop zejula addit
indic compani tesaro stage develop
earli commerci yet profit
primarili focu potenti futur revenu valu base
expect tesaro grow unit sale first
two product add addit indic geographi
zejula next year estim total revenu
grow compound-annual-growth-rate next five year increas
billion
estim tesaro total revenu grow billion
million product revenu expect
grow billion million
growth estim result continu sale growth zejula
estim zejula sale includ addit indic
increas billion account revenu
avanova data recurr ovarian cancer
submiss snda fda quadra studi
bla submiss patient msi-h cancer
estim sale growth two commerci product
low could meaning upsid earn estim
believ unlik addit product tesaro
pipelin could contribut sale could possibl
advanc quickli estim
estim total contribut growth zejula
current approv indic gain approv addit
indic zejula fail penetr market
gain addit indic revenu would reduc
million ep
accord proprietari databas averag forward price-to-sal multipl biotechnolog sector current
discount estim revenu risk-of-failur billion discount invest return arriv
month target price
believ greatest risk tesaro stock next five year zejula gain market penetr second-lin
ovarian cancer set gain approv front-lin ovarian set calcul combin impact event
model could reduc estim revenu million suggest stock could valu rang
rate tesaro commercial-stag biotechnolog compani recent launch
excit oncolog drug outperform target price anticip tesaro
continu develop commerci drug zejula varubi compani tesaro
stage develop earli commerci yet profit primarili focu
potenti futur revenu valu base expect tesaro grow unit
sale zejula add addit indic geographi zejula next
year estim total revenu grow compound-annual-growth-rate next five year
increas billion zejula treatment ovari cancer princip
driver growth believ estim revenu achiev howev
case development-stag compani estim carri degre risk
accord proprietari databas averag forward price-to-sal multipl
biotechnolog sector current discount estim revenu risk-of-
failur invest return arriv target price
believ greatest risk tesaro stock next five year zejula
gain market penetr second-lin ovarian cancer set gain approv
front-lin ovarian set calcul combin impact event
model could reduc estim revenu million suggest stock
could valu rang
analysi
tesaro releas result today zejula sale million exceed
estim million consensu million better
estim sale result unit demand increas strong growth outsid us
total revenu million lower estim million due varubi
collabor revenu million lower estim million
consensu million total oper expens million higher
estim million due lower estim expens tesaro lost
per share compar estim loss per share consensu loss
per share detail analysi quarter list exhibit
exhibit varianc analysi tesaro
tesaro nasdaq-tsro incom statement thousand except per share data estimatedactualvari bp consensusvari bp chang bp chang product revenu relat good share share incom per per share dilut compani data oppenheim co estimatesaddit inform avail upon request line guidanceprevi revenu net millionzejula millionzejula millionoth revenu includ licens varubi millioninterest expens million includ non-cash interest expens million includ non-cash interest expens millioncash cash million tsro outperform
zejula outlook basic unchang adjust revenu
outlook tesaro account lower estim varubi sale increas
estim account current level pipelin invest
along adjust net interest expens result loss per share
slightli increas ep reduc chang
outlin exhibit
exhibit product sale revenu expens earn adjust compar prior estim tesaro
tesaro nasdaq-tsro incom statement thousand except per share data priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang product revenu relat good nminterest share share incom per per share dilut compani data oppenheim co estimatesaddit inform avail upon request tesaro inc
tesaro announc websit
septemb tesaro announc initi second stage
jasper studi design assess clinic benefit zejula niraparib
combin antibodi first-lin non-smal cell lung cancer
nsclc patient note jasper studi proce stage earli
evid import nsclc market potenti upsid
confer call tesaro announc initi phase first
trial zejula /- bevacizumab first-lin ovarian cancer
tesaro announc prepar underway initi phase ii
registration-en trial vs standard-of-car first-lin lung cancer
tesaro announc prepar underway partner janssen
futur phase trial assess benefit zejula combin
abirateron acet prednison mcrpc patient
tesaro announc enrol phase prima trial zejula
monotherapi patient first-lin ovarian cancer regardless biomark
statu complet
tesaroproduct studyindicationpartner/ otherdiscoverypre-clinicaliiiiiifiledapprovedmarketedrolapit tablet chemotherapy-induc nausea/vomitingrolapit iv chemotherapy-induc nausea/vomitingzejula niraparib novaovarian cancer platinum-sensit maintenanceprimaovarian cancer mainten frontlin therapyquadraovarian cancer prior regimen topaciotnbc ovarian pembrolizumabavanovaovarian cancer bevacizumabengotew sarcoma chemotherapysarcfirst line ovarian tnbc brca-mut breast cancergalahadmetastat castration-resist prostat cancerjanssenbediveremetastat castration-resist prostat cancer apalutamid abirateron acet prednisonejanssenovarian cancer recurr bevacizumab plan ovarioovarian cancer line bevacizumabadvanc nsclc high plan jasperadvanc nsclc/squamou cell carcinoma line ovarian /- bevacizumabplatinum-resistant/refractori ovarian metastat tumor w/ carboplatin-paclitaxelgarnetmsi-h tumorsovarian cancer first-lin zejula nsclc solid variou tumorssmal molecul i-o targetsvari tumorsengot european network gynaecolog oncolog trial groupssarc sarcoma allianc research collaborationclin trial tsro outperform
regulatori decis file data releas
tesaro announc zejula approv countri
reimburs launch germani itali sever
european countri tesaro expect launch five major european
countri germani franc itali spain
octob tesaro partner zai lab limit announc zejula
approv hong kong zejula first parp inhibitor
approv hong kong mainten treatment platinum-sensit
relaps ovarian cancer regardless brca mutat statu
tesaro announc expect submit snda quadra studi
late-lin ovarian cancer beyond brcamut patient near year-end
confer call tesaro announc target submiss
supplement new drug applic snda zejula late-lin treatment
ovarian patient beyond brca mutat base quadra
ye
tesaro reiter garnet studi intend support bla
submiss fda
octob tesaro announc achiev develop mileston
trigger million payment janssen mileston
relat janssen on-going phase ii galahad trial assess niraparib
monotherapi treatment men metastat castration-resist
prostat cancer mcrpc dna-repair anomali data trial
anticip support global regulatori file
confer call tesaro announc top-lin data phase
prima trial zejula first-lin ovarian cancer mainten therapi
expect late
confer call tesaro announc expect data result
phase ii avanova trial zejula vs zejula bevacizumab avail
year-end submiss medic meet
tesaro announc expect top-lin data avail phase ii
ovario trial zejula bevacizumab first-lin ovarian cancer
tesaro announc expect addit present data phase
garnet trial lung cancer patient cohort
expect data avail msi-h tumor
tesaro announc expect present addit data phase ii
jasper trial zejula first-lin lung cancer medic
meet
tesaro announc expect present initi data phase amber
combin trial advanc solid tumor
societi immunotherapi cancer confer novemb
expect present cohort expans data
tesaro announc plan submit data bravo trial zejula
germlin brca-mut breast cancer patient public
octob european societi medic oncolog esmo confer
tesaro present data phase ib bediver trial demonstr
safeti toler combin zejula abirateron acet
prednison aa-p men mcrpc data bediver trial
use inform dose regimen futur phase trial assess
clinic benefit zejula combin aa-p mcrpc patient
octob esmo tesaro present data zejula quadra
prima studi outlin ovario studi recruit patient
quadra demonstr durabl clinic activ late-lin greater
product candidateindicationstudyexpect time endometrialgarnetesmo oct cancergarnetsitc single-agentcancercitrinositc ovarianprimal bevacizumabfirst-lin tsro outperform
fourthlin patient brcamut tumor overal respons rate orr
approxim includ patient platinum-sensit -resist
refractori diseas median durat respons month prima
data evalu patient greater day safeti data
blind pool niraparib placebo indic improv toler
niraparib individu start dose teae lead treatment
discontinu remain low group fix start dose
individu start dose group note zejula data
present esmo quadra prima
octob esmo tesaro present updat phase garnet data tsr-
antibodi patient recurr advanc microsatellit
instabl high msi-h endometri cancer cohort tesaro report
time data cutoff patient msi-h endometri cancer receiv
treatment tesaro reiter garnet studi intend
support bla submiss fda note garnet
data present esmo support expect bla
provid summari financi outlook full financi
model product detail avail upon request
tesaro nasdaq-tsro oppenheim co estim sale earningsleah rush cann million except per share statement product product revenu relat growth incom share share per share basic continu per share compani data oppenheim co estimatesaddit inform avail upon request tsro outperform
stock price compani mention report
janssen divis -nyse cover
